Diadema Partners LP Sellas Life Sciences Group, Inc. Transaction History
Diadema Partners LP
- $328 Billion
- Q2 2025
A detailed history of Diadema Partners LP transactions in Sellas Life Sciences Group, Inc. stock. As of the latest transaction made, Diadema Partners LP holds 400,000 shares of SLS stock, worth $664,000. This represents 0.27% of its overall portfolio holdings.
Number of Shares
400,000Holding current value
$664,000% of portfolio
0.27%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding SLS
# of Institutions
93Shares Held
23.2MCall Options Held
1.3MPut Options Held
59.3K-
Vanguard Group Inc Valley Forge, PA6.65MShares$11 Million0.0% of portfolio
-
Marshall Wace, LLP London, X02.72MShares$4.51 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA2.2MShares$3.65 Million0.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA1.49MShares$2.47 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.13MShares$1.87 Million0.0% of portfolio
About SELLAS Life Sciences Group, Inc.
- Ticker SLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,551,900
- Market Cap $34.1M
- Description
- SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the tr...